BioLineRx (NASDAQ:BLRX) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of BioLineRx (NASDAQ:BLRX) in a report issued on Friday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright decreased their target price on BioLineRx from $21.00 to $9.00 and set a “buy” rating on the stock in a research report on Monday, November 25th.

BioLineRx Stock Performance

BLRX opened at $0.27 on Friday. The company has a 50 day simple moving average of $0.32 and a two-hundred day simple moving average of $0.52. The company has a debt-to-equity ratio of 2.11, a current ratio of 1.52 and a quick ratio of 1.37. The firm has a market cap of $21.89 million, a P/E ratio of -1.24 and a beta of 1.39. BioLineRx has a 1-year low of $0.19 and a 1-year high of $1.58.

Institutional Trading of BioLineRx

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Atria Investments Inc raised its holdings in BioLineRx by 27.9% in the 3rd quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock valued at $72,000 after acquiring an additional 29,193 shares during the last quarter. PVG Asset Management Corp acquired a new position in shares of BioLineRx during the 2nd quarter worth approximately $70,000. Finally, CVI Holdings LLC purchased a new stake in shares of BioLineRx in the second quarter valued at approximately $462,000. 1.56% of the stock is owned by institutional investors and hedge funds.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.